trending Market Intelligence /marketintelligence/en/news-insights/trending/m8zlju99iodv4cizwlyk9q2 content esgSubNav
In This List

Pfizer settles patent claims, wins in J&J biosimilar case

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Pfizer settles patent claims, wins in J&J biosimilar case

Pfizer Inc. provided updates on three cases in a Form 10-Q filing for the quarter ended July 1.

The company settled its patent infringement claims against Apotex and Actavis, on terms not material to the New York-based drugmaker.

The claims are over Xtandi, the prostate cancer drug Pfizer co-owns with Astellas Pharma Inc. In 2016, the Japanese drugmaker sued drugmakers including Apotex Inc., Apotex Corp., Actavis LLC and Actavis Laboratories FL Inc., saying their generic versions of Xtandi infringed on its patents.

Separately, the U.S. District Court for the District of Massachusetts ruled against Johnson & Johnson in a patent case it brought against Pfizer. The New Jersey-based pharmaceutical giant said Inflectra, Pfizer's biosimilar version of its cancer drug Remicade, infringed on its patents relating to antibodies and cell culture media. The court ruled that the cell culture media patent was not infringed.

The Court of Appeals for the Federal Circuit had ruled that Pfizer did not infringe on Johnson & Johnson's antibody patent in January.

Meanwhile, the U.K. Competition & Markets Authority, or CMA, in June sought reinstate a £84.2 million fine against Pfizer and its U.K.-based unit Pfizer Ltd. The Competition Appeal Tribunal previously overturned the fine, which was imposed due to Pfizer's alleged antitrust violations in supplying phenytoin sodium capsules to the U.K. market.